QuickView for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=D6CE45891B758B23072D12349DA813EB;jsessionid=A78ED1FEEC9A13DD17CCC8E3368A4B4D;jsessionid=34F78AEAC45B3D6F9198308E1B9292C7;jsessionid=0339FBA773B6C1617357E2DB9FFBA954;jsessionid=73C6CBC806CE2D96284876F1D37C968A;jsessionid=BB1AA7667FC8D4A8D1AFBE04CD8288C6;jsessionid=EC0B98DFA0E4AE264180CAC7C820CE8D (gene)

1. ATXN2 intermediate expansions in amyotrophic lateral sclerosis.
2. Missense mutation in ATXN2 gene (c.2860C > T) in an amyotrophic lateral sclerosis patient with aggre…
3. The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissue…
4. Ataxin-2 gene: a powerful modulator of neurological disorders.
5. Antagonistic roles for Ataxin-2 structured and disordered domains in RNP condensation.

There were no clinical trials for TNRC13;jsessionid=3D765BD25ABDC6EF1EDE0A75B9F1BD6C;jsessionid=84A7B1B8F90E10C4BB8EF198E8862C87;jsessionid=086624F9ED561E2247AC960DF604F403;jsessionid=D6CE45891B758B23072D12349DA813EB;jsessionid=A78ED1FEEC9A13DD17CCC8E3368A4B4D;jsessionid=34F78AEAC45B3D6F9198308E1B9292C7;jsessionid=0339FBA773B6C1617357E2DB9FFBA954;jsessionid=73C6CBC806CE2D96284876F1D37C968A;jsessionid=BB1AA7667FC8D4A8D1AFBE04CD8288C6;jsessionid=EC0B98DFA0E4AE264180CAC7C820CE8D